FDA grants traditional approval to Novartis’ Fabhalta for IgAN Pharmaceutical Technology 11:48 Fri, 17 Jul
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN Novartis (Press Release) 01:06 Fri, 17 Jul
